FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors
1 Servei de Patologia, Laboratori de Citogenètica Molecular, Hospital del Mar, IMAS, GRETNHE, IMIM, 08003 Barcelona, Spain
2 Departament de Biologia Cellular, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
3 Escola de Citologia Hematològica S Woessner-IMAS, 08003 Barcelona, Spain
4 Department of Pathology, University of Debrecen MHSC, 4032 Debrecen, Hungary
5 Servei de Patologia, Unitat de Patologia Mamària, Hospital del Mar, UAB, 08003 Barcelona, Spain
6 Molecular Therapeutics and Biomarkers in Breast Cancer Program, IMIM-Hospital del Mar, 08003 Barcelona, Spain
7 Capio-Fundación Jiménez Díaz, 28040 Madrid, Spain
8 Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain
9 Escola Bonanova-IMAS, 08003 Barcelona, Spain
10 Oncology Department, Hospital del Mar, 08003 Barcelona, Spain
Breast Cancer Research 2009, 11:402 doi:10.1186/bcr2239
See related research article by Götte et al., http://breast-cancer-research.com/content/9/1/R8
Published: 21 April 2009First paragraph (this article has no abstract)
In their report, Götte and coworkers [1] analyzed the expression of c-Met in 200 patients with ductal carcinoma in situ. They concluded that c-Met could be related to angiogenic and lymphangiogenic factors in ductal carcinoma in situ. On the other hand, Greenberg and coworkers [2] studied 31 patients with ductal infiltrating carcinoma (DIC) to detect c-Met expression in their axillary fluids. They observed a correlation of c-Met expression with increasing tumor size and grade, capillary and lymphatic invasion and lymph node metastasis.
